Bayer Says Xarelto Gets Partial Extension of European Patent

Oct. 29, 2021, 9:40 AM

Bayer AG said its blood-thinner Xarelto will be partly patent-protected through January 2026, citing a ruling from the European patent office.

  • Patent office reversed a prior decision and will prevent generic competition for the drug when it comes to daily dosing of 10, 15 and 20mg, Bayer says in statement
  • Ruling doesn’t affect 2.5mg dosing of the product
  • Bayer got about half of its 4.5 billion euros ($5.2 billion) revenue for Xarelto in EMEA region last year, spokesman said in phone interview
  • Majority of Xarelto sales in EMEA come from daily dosings of 10, 15 and 20mg, spokesman said
  • Decision ...

To read the full article log in.

Learn more about a Bloomberg Law subscription